BioMarin drug trial meets one of two primary goals in rare disease study

May 18, 2026 9:05 AM

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its Phase 3 ENERGY 3 trial for BMN 401 in children with ENPP1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found